Oppenheimer & CO Inc Alaunos Therapeutics, Inc. Transaction History

Oppenheimer & CO Inc

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.04 - $322.5 $9,360 - $2.9 Million	-9,000 Reduced 19.78%	36,500 $63,000
Q2 2022 Aug 08, 2022	SELL	$0.41 - $1.24 $10,455 - $31,620	-25,500 Reduced 35.92%	45,500 $56,000
Q4 2021 Feb 02, 2022	SELL	$1.09 - $1.89 $62,457 - $108,297	-57,300 Reduced 44.66%	71,000 $77,000
Q3 2021 Nov 12, 2021	SELL	$1.44 - $2.73 $50,400 - $95,550	-35,000 Reduced 21.43%	128,300 $233,000
Q2 2021 Aug 03, 2021	BUY	$2.63 - $3.67 $209,085 - $291,765	79,500 Added 94.87%	163,300 $431,000
Q1 2021 May 10, 2021	BUY	$2.82 - $5.6 $154,536 - $306,880	54,800 Added 188.97%	83,800 $301,000
Q3 2019 Oct 31, 2019	BUY	$4.13 - $6.94 $4,130 - $6,940	1,000 Added 3.57%	29,000 $125,000
Q2 2019 Aug 09, 2019	SELL	$3.98 - $6.2 $31,840 - $49,600	-8,000 Reduced 22.22%	28,000 $163,000
Q1 2019 Apr 24, 2019	BUY	$2.0 - $4.4 $2,000 - $4,400	1,000 Added 2.86%	36,000 $139,000
Q4 2018 Jan 29, 2019	BUY	$1.61 - $3.62 $38,640 - $86,880	24,000 Added 218.18%	35,000 $65,000
Q2 2018 Aug 10, 2018	SELL	$3.02 - $4.94 $6,040 - $9,880	-2,000 Reduced 15.38%	11,000 $33,000
Q1 2018 May 01, 2018	SELL	$3.46 - $5.14 $1,384 - $2,056	-400 Reduced 2.99%	13,000 $51,000
Q4 2017 Feb 07, 2018	SELL	$4.0 - $6.54 $2,400 - $3,924	-600 Reduced 4.29%	13,400 $55,000
Q3 2017 Nov 09, 2017	BUY	$4.99 - $6.57 $69,860 - $91,980	14,000	14,000 $86,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.